Identification of Novel CDH1-NRG2α and F11R-NRG2α Fusions in NSCLC Plus Additional Novel NRG2α Fusions in Other Solid Tumors by Whole Transcriptome Sequencing-Reference-Cited by-同舟云学术

Identification of Novel CDH1-NRG2α and F11R-NRG2α Fusions in NSCLC Plus Additional Novel NRG2α Fusions in Other Solid Tumors by Whole Transcriptome Sequencing

Published:2021-02 Issue:2 Volume:2 Page:100132
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Ou Sai-Hong Ignatius,Xiu Joanne,Nagasaka Misako,Xia Bing,Zhang Shannon S.,Zhang Qing,Swensen Jeffrey J.,Spetzler David,Korn Wolfgang Michael,Zhu Viola W.,Liu Stephen V.

Publisher

Elsevier BV

Reference15 articles.

1. Identification of novel CD74-NRG2α fusion from comprehensive profiling of lung adenocarcinoma in Japanese never or light smokers;Kohsaka;J Thorac Oncol,2020

2. Is NRG2α fusion a “Doppelgänger” to NRG1α/β fusions in oncology?;Nagasaka;J Thorac Oncol,2020

3. Detection of NRG1 gene fusions in solid tumors;Jonna;Clin Cancer Res,2019

4. Response to ERBB3-directed targeted therapy in NRG1-rearranged cancers;Drilon;Cancer Discov,2018

5. Neuregulin 1 fusion-positive NSCLC;Nagasaka;J Thorac Oncol,2019

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pulmonary invasive mucinous adenocarcinoma;Histopathology;2023-10-22

2. SPON1 is an independent prognostic biomarker for ovarian cancer;Journal of Ovarian Research;2023-05-13

3. Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics;Pharmaceuticals;2023-04-19

4. Recent progress in targeted therapy for non-small cell lung cancer;Frontiers in Pharmacology;2023-02-21

5. Rare molecular subtypes of lung cancer;Nature Reviews Clinical Oncology;2023-02-20